EFFECT OF INSULIN INDUCED HYPOGLYCAEMIA ON THE BLOOD LEVELS OF CATECHOLAMINES, GLUCAGON, GROWTH HORMONE, CORTISOL, C-PEPTIDE AND PROINSULIN BEFORE AND DURING MEDICATION WITH THE CARDIOSELECTIVE BETA-RECEPTOR BLOCKING AGENT METOPROLOL IN MAN

1978 ◽  
Vol 87 (3) ◽  
pp. 659-667 ◽  
Author(s):  
Bernt Hökfelt ◽  
Bengt-Göran Hansson ◽  
Lise G. Heding ◽  
Karl Olof Nilsson
Keyword(s):  
Growth Hormone ◽  
Moderate Hypertension ◽  
Limit Of Detection ◽  
Plasma Catecholamines ◽  
Blocking Agent ◽  
Blood Levels ◽  
Exogenous Insulin ◽  
Maximal Dose ◽  
C Peptide ◽  
Receptor Blocking

ABSTRACT Studies were performed in 8 males with moderate hypertension to explore the influence of metoprolol on the sensitivity to insulin and on the response to hypoglycaemia with respect to plasma catecholamines, glucagon, growth hormone and cortisol. C-peptide and proinsulin were determined in some instances. All subjects were studied before treatment, after one month on placebo and after 3 months on metoprolol. The final maximal dose used was 50–150 mg three times daily. The sensitivity to insulin was the same during all three conditions studied. The response in catecholamines, glucagon, growth hormone and cortisol following insulin induced hypoglycaemia was similar during placebo as compared to no treatment. Adrenaline, growth hormone and cortisol showed a greater response to hypoglycaemia during metoprolol whereas no difference was seen with respect to noradrenaline and glucagon. The half-life of exogenous insulin was the same before and during metoprolol (7.6 min). Metoprolol caused no changes in the basal C-peptide levels. During the hypoglycaemic phase C-peptide showed a continuous gradual fall, which was similar before and during metoprolol. Proinsulin was below the lower limit of detection before and following the injection of insulin both without treatment and during metoprolol.

Long term treatment of moderate hypertension with the beta1-receptor blocking agent metoprolol

1977 ◽  
Vol 11 (4) ◽  
pp. 239-245 ◽  
Author(s):  
B. -G. Hansson ◽  
J. -F. Dymling ◽  
H. Hedeland ◽  
U. L. Hulth�n
Keyword(s):  
Moderate Hypertension ◽  
Blocking Agent ◽  
Term Treatment ◽  
Receptor Blocking ◽  
Long Term Treatment

Pulsatile Growth Hormone and Prolactin: Effects of (+) Butaclamol, a Dopamine Receptor Blocking Agent

Endocrinology ◽  
1977 ◽  
Vol 101 (4) ◽  
pp. 1298-1303 ◽  
Author(s):  
J. O. WILLOUGHBY ◽  
P. BRAZEAU ◽  
J. B. MARTIN
Keyword(s):  
Growth Hormone ◽  
Dopamine Receptor ◽  
Blocking Agent ◽  
Receptor Blocking

The role of the growth hormone in assisted reproductive technologies cycles

GYNECOLOGY ◽  
2019 ◽  
Vol 21 (4) ◽  
pp. 6-8
Author(s):  
Andrey Y Romanov ◽  
Anastasiya G Syrkasheva ◽  
Nataliya V Dolgushina ◽  
Elena A Kalinina
Keyword(s):  
Growth Hormone ◽  
Live Birth ◽  
Ovarian Stimulation ◽  
Assisted Reproductive Technologies ◽  
Polycystic Ovary ◽  
Live Birth Rate ◽  
Reproductive Technologies ◽  
Blood Levels ◽  
Main Research ◽  
Poor Ovarian Responders

The paper analyzes the literature data on the use of the growth hormone (GH) in ovarian stimulation in assisted reproductive technologies (ART). Routine use of GH in ovarian stimulation in patients with a normal GH level does not increase pregnancy and childbirth rates in ART. Also, no benefits of using GH have been identified for patients with polycystic ovary syndrome, despite the increase in insulin and IGF-1 blood levels. The main research focus is to study the use of GH in patients with poor ovarian response. According to the meta-analysis conducted by X.-L. Li et al. (2017), GH in ovarian stimulation of poor ovarian responders increases the number of received oocytes, mature oocytes number, reduces the embryo transfer cancellation rate and does not affect the fertilization rate. The pregnancy and live birth rates are significantly higher in the group of GH use - by 1.65 (95% CI 1.23-2.22) and 1.73 (95% CI 1.25-2.40) times, respectively. Thus, it is advisable to use GH in ovarian stimulation in poor ovarian responders, since it allows to increases live birth rate in ART. However, further studies should determine the optimal GH dose and assesse it`s safety in ART programs.

Different short-term effect of protein and carbohydrate intake on TSH, growth hormone (GH), insulin, C-peptide, and glucagon in humans

1990 ◽  
Vol 50 (7) ◽  
pp. 801-805 ◽  
Author(s):  
L. E. Matzen ◽  
B. B. Andersen ◽  
B. G. Jensen ◽  
H. J. Gjessing ◽  
S. H. Sindrup ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Term Effect ◽  
Carbohydrate Intake ◽  
Short Term ◽  
C Peptide ◽  
Short Term Effect

scholarly journals Effects of Late Conversion from Twice-Daily to Once-Daily Slow Release Tacrolimus on the Insulin Resistance Indexes in Kidney Transplant Patients

2021 ◽  
Vol 2 (1) ◽  
pp. 49-56
Author(s):  
Valeria Cademartori ◽  
Fabio Massarino ◽  
Emanuele L. Parodi ◽  
Ernesto Paoletti ◽  
Rodolfo Russo ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Kidney Transplant ◽  
Slow Release ◽  
Density Lipoprotein ◽  
Blood Levels ◽  
Transplant Recipients ◽  
Once Daily ◽  
C Peptide ◽  
Transplant Patients ◽  
Kidney Transplant Patients

The use of tacrolimus (Tac) may be involved in the development of new-onset diabetes after transplantation (NODAT) in a dose-related manner. This study aimed to evaluate the effects of a standard twice-daily formulation of Tac (TacBID) vs. the once-daily slow-release formulation (TacOD) on the basal insulin resistance indexes (Homa and McAuley), and related metabolic parameters, in a cohort of kidney transplant patients. We retrospectively evaluated 20 stable renal transplant recipients who were switched from TacBID to TacOD. Blood levels of Tac were analyzed at one-month intervals from 6 months before to 8 months after conversion. Moreover, Homa and McAuley indexes, C-peptide, insulin, HbA1c, uric acid, triglycerides, low-density lipoprotein (LDL) and high-density lipoprotein (HDL)-cholesterol serum levels and their associations with Tac levels were evaluated. We observed a significant decrease in Tac exposure (8.5 ± 2 ng/mL, CV 0.23 vs. 6.1 ± 1.9 ng/mL, CV 0.31, TacBID vs. TacOD periods, p < 0.001) and no significant changes in Homa (1.42 ± 0.4 vs. 1.8 ± 0.7, p > 0.05) and McAuley indexes (7.12 ± 1 vs. 7.58 ± 1.4, p > 0.05). Similarly, blood levels of glucose, insulin, HbA1c, lipids, and uric acid were unchanged between the two periods, while C-peptide resulted significantly lower after conversion to TacOD. These data suggest that in kidney transplant recipients, reduced Tac exposure has no significant effects on basal insulin sensitivity indexes and metabolic parameters.

Sign in / Sign up

Export Citation Format

Share Document